Raised funds through a third-party allocation of new shares from Keio Innovation Initiative, Inc.

PURMX Therapeutics, Inc. (PURMX Therapeutics; Headquarters: Hiroshima, Japan; President: Hidetoshi Tahara; hereafter “the Company”) is pleased to report that it has issued new shares through a third-party allotment to KII No. 3 Impact Investment Limited Liability Partnership. This third-party allotment brings PURMX Therapeutics' cumulative total raised to approximately 1.2 billion yen (7.8 million USD).

Press release_Apr 2024_Series A.pdf

Download PDF • 317KB